We have established three highly synergistic technology platforms. The structural biology platform enables rational small-molecule design through in-depth understanding of disease-relevant targets, protein structures, and key molecular interactions. The AI-powered drug design platform integrates computational chemistry, molecular modeling, and data-driven algorithms to accelerate lead optimization and clinical candidate selection. The clinically relevant disease model platform emphasizes translational in vitro and in vivo systems to validate mechanisms of action and predict efficacy and safety, improving the probability of clinical success.

In hematology, one of our lead assets, flonoltinib maleate (FM), is being developed to establish a new standard of care for myeloproliferative neoplasms. FM is a proprietary JAK2/FLT3/CDK6 inhibitor designed to address key disease drivers in myelofibrosis, with the goal of delivering durable spleen and symptom improvement while maintaining a manageable safety profile across a broad patient population. FM has demonstrated competitive efficacy and safety signals in multiple clinical studies and is currently being evaluated in a Phase 3 registrational trial in China, alongside ongoing overseas clinical and regulatory interactions.

In oncology, purinostat mesylate (PM) represents another late-stage lead asset of us. PM is a highly selective, next-generation HDAC I/IIb inhibitor enabled by a differentiated molecular design, aimed at enhancing antitumor activity while improving tolerability. PM is primarily being developed for B- and T-cell malignancies and multiple myeloma, where it has shown promising efficacy and a predictable, manageable safety profile in early- and mid-stage studies, and has been granted conditional approval pathway in China. We have continued to advance PM’s development while exploring its potential in combination regimens and additional oncologic indications.